Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,384 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Denver, Colorado Clear all
Terminated Phase 3 Interventional Results available

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT04419558
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Jul 25, 2026, 8:09 AM EDT
Active, not recruiting Phase 3 Interventional

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurotoxicity
Interventions
temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

NCT00094055
View directory record Official record
Conditions
Thyroid Neoplasms
Interventions
AG013736
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
9
States / cities
Santa Monica, California • Aurora, Colorado • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

NCT00036543
View directory record Official record
Conditions
Prostate Cancer
Interventions
Atrasentan
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
79
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2006 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

NCT01110889
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jul 25, 2026, 8:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ImmuneSense COVID-19 Variant Study

NCT05054088
View directory record Official record
Conditions
Covid19
Interventions
T-Detect COVID test
Device
Lead sponsor
Adaptive Biotechnologies
Industry
Eligibility
18 Years to 89 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 4 Interventional Results available

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

NCT01430403
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS), Placebo omalizumab, Placebo fluticasone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 25, 2026, 8:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Interventions
Brepocitinib PO QD, Placebo PO QD
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
53
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677569
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 25, 2026, 8:09 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

NCT04334941
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
561
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

NCT02696031
View directory record Official record
Conditions
Non-radiographic Spondyloarthritis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Fullerton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Not applicable Interventional Results available

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

NCT02542631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding

NCT00331188
View directory record Official record
Conditions
Esophageal Varices, Portal Hypertension, Gastric Varices, Esophageal Bleeding
Interventions
Sanvar® (vapreotide)
Drug
Lead sponsor
Debiovision
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2008 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

NCT02101788
View directory record Official record
Conditions
Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Topotecan, Trametinib Dimethyl Sulfoxide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
488
States / cities
Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 25, 2026, 8:09 AM EDT
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Not applicable Interventional Results available

Retrospective Independent Safety Review of Closed Irrisept Study

NCT05359666
View directory record Official record
Conditions
Adverse Events
Interventions
Irrisept, Standard of Care
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
Not listed
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 25, 2026, 8:09 AM EDT
Active, not recruiting Phase 2 Interventional

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

NCT06940154
View directory record Official record
Conditions
COPD Acute Exacerbation
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 25, 2026, 8:09 AM EDT
Recruiting Phase 2Phase 3 Interventional

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

NCT03851445
View directory record Official record
Conditions
Previously Treated Non-Small Cell Lung Cancer
Interventions
Screening Platform
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1229
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 25, 2026, 8:09 AM EDT
Completed No phase listed Observational

The AVERT Sepsis Investigation

NCT01968746
View directory record Official record
Conditions
Sepsis, Severe Sepsis
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Denver, Colorado • Newark, Delaware • Billings, Montana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

NCT00263588
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
28
States / cities
San Francisco, California • Vallejo, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Jul 25, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 25, 2026, 8:09 AM EDT